Article

Botulinum toxin products display warnings, receive name changes

The FDA announced that four botulinum toxin drug products now have boxed warnings on their labels and include medication guides that explain the risk of adverse events to patients, as directed by the agency in April.

Silver Spring, MD

-The FDA announced that four botulinum toxin drug products now have boxed warnings on their labels and include medication guides that explain the risk of adverse events to patients, as directed by the agency in April.

The warnings caution that the effects of the botulinum toxin may spread from the area of the injection to other areas of the body, causing symptoms similar to those of botulism, including life-threatening breathing and swallowing problems and death, according to a prepared statement issued by the FDA. Symptoms have been reported in adults treated for approved and unapproved uses and children with cerebral palsy being treated for muscle spasticity.

No definitive serious adverse events of distant spread of toxin associated with botulinum toxin type A (Botox, Allergan) have been reported when the drug is used at approved doses for eyelid twitches or for crossed eyes, the agency said.

The four affected products, three of which also received changes to their established drug (or generic) names to prevent medication errors, are:
• Botox, Allergan (new name: onabotulinumtoxinA)
• Botox Cosmetic, Allergan (new name: onabotulinumtoxinA)
• Myobloc, Solstice Neurosciences (new name: rimabotulinumtoxinB)
• Dysport, Ipsen (approved in April with the boxed warning and not experiencing a name or label change)

The revised labels also emphasize that the drugs are not interchangeable, because the units used to measure the products are different, according to the FDA. Neither the brand names nor the formulations have changed.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.